Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nanna Nyholm, Anne Danø, Henrik Schnack & Giorgio Lorenzo Colombo. (2023) The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis. ClinicoEconomics and Outcomes Research 15, pages 607-619.
Read now
Read now
Nanna Nyholm, Henrik Schnack, Anne Danø & François Skowron. (2023) Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany. Current Medical Research and Opinion 39:6, pages 833-842.
Read now
Read now
Pieralessandro Lasalvia, Yaneth Gil-Rojas, Emmanuel Papadimitropoulos, Russel Burge & Diego Rosselli. (2023) Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods. Expert Review of Pharmacoeconomics & Outcomes Research 23:5, pages 511-517.
Read now
Read now
Philip Hampton, Emma Borg, Jes Birger Hansen & Matthias Augustin. (2021) Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison. Psoriasis: Targets and Therapy 11, pages 123-131.
Read now
Read now
Alexander Egeberg, Anne Danø, Mikkel H. Pedersen, Anne Sohrt, Emma Borg & Jaime Notario. (2021) Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. Journal of Medical Economics 24:1, pages 1134-1142.
Read now
Read now
Articles from other publishers (32)
Corey L Snyder, Ruby S Gibson, Martina L Porter & Alexa B Kimball. (2023) Secukinumab in the treatment of hidradenitis suppurativa. Immunotherapy 15:17, pages 1449-1457.
Crossref
Crossref
Andrew Blauvelt & Megan H. Noe. (2023) The Best Psoriasis Medications Emerge. JAMA Dermatology.
Crossref
Crossref
Ahmed Ibrahim AbdElneam, Mohammed Saleh Al‐Dhubaibi, Saleh Salem Bahaj, Mohammad Arshad, Ghada Farouk Mohammed & Lina Mohamed Atef. (2023) The CDX2 G allele and the FoKI F allele of the VDR gene are more prevalent and related to changes in vitamin D levels in patients with psoriasis vulgaris: A pilot study. Skin Research and Technology 29:11.
Crossref
Crossref
Peter Foley, Kurt Gebauer, John Sullivan, Erin McMeniman, Stephen Shumack, Jonathan Ng, Amelia James, Morton Rawlin, Shireen Sidhu, Dev Tilakaratne, Murray Turner, Barbara Radulski, Peter Nash & Christopher Baker. (2023) Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients. Australasian Journal of Dermatology 64:4, pages 476-487.
Crossref
Crossref
Xuân-Lan Lam Hoai & Thierry Simonart. (2023) Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis. Journal of Clinical Medicine 12:16, pages 5410.
Crossref
Crossref
Thomas Bieber. (2023) Disease modification in inflammatory skin disorders: opportunities and challenges. Nature Reviews Drug Discovery 22:8, pages 662-680.
Crossref
Crossref
Emilie Sbidian, Anna Chaimani, Robin Guelimi, Ignacio Garcia-Doval, Camille Hua, Carolyn Hughes, Luigi Naldi, Maria Kinberger, Sivem Afach & Laurence Le Cleach. (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Qingfang Yuan, Na Peng, Fan Xiao, Xiaofei Shi, Bo Zhu, Ke Rui, Jie Tian & Liwei Lu. (2023) New insights into the function of Interleukin-25 in disease pathogenesis. Biomarker Research 11:1.
Crossref
Crossref
Lisa Schots, Rani Soenen, Brigitte Blanquart, Debby Thomas & Jo Lambert. (2023)
Blocking interleukin‐17 in psoriasis: Real‐world experience from the
PsoPlus
cohort
. Journal of the European Academy of Dermatology and Venereology 37:4, pages 698-710.
Crossref
Crossref
Dharshna Balamurugan, Chintamani Nayak, Abhijit Chattopadhyay, Avaranjika Karuppusamy, Maria Malathi Ambrose, Ashwani Kumar, Navin Kumar Singh, Munmun Koley & Subhranil Saha. (2023) Individualized Homeopathic Medicines in the Treatment of Psoriasis Vulgaris: Double-Blind, Randomized, Placebo-Controlled Trial. Complementary Medicine Research 30:4, pages 317-331.
Crossref
Crossref
Mohammad Zaki Ahmad, Abdul Aleem Mohammed, Mohammed S. Algahtani, Awanish Mishra & Javed Ahmad. (2022) Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope. Journal of Functional Biomaterials 14:1, pages 19.
Crossref
Crossref
Ghadah Alhetheli, Mohammed S Al-Dhubaibi, Saleh S Bahaj & Ahmed AbdElneam. (2022) Vitamin D Receptor Gene Polymorphism ApaI as a Predisposing Factor for Psoriasis and Its Relation With Serum Vitamin D Levels and Psoriasis Severity. Cureus.
Crossref
Crossref
Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour & Joachim Marti. (2022) Current Expertise, Opinions, and Attitude toward TNF-⍺ Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland. Healthcare 10:11, pages 2152.
Crossref
Crossref
Robin Guelimi, Sivem Afach, Jean Philippe Régnaux, Thomas Bettuzzi, Guillaume Chaby, Emilie Sbidian, Florian Naudet & Laurence Le Cleach. (2022) Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality. British Journal of Dermatology 187:1, pages 29-41.
Crossref
Crossref
Craig L. Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts & Richard B. Warren. (2022) Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Advances in Therapy 39:5, pages 2256-2269.
Crossref
Crossref
Julie J. Hong, Edward K. Hadeler, Megan L. Mosca, Nicholas D. Brownstone, Tina Bhutani & Wilson J. Liao. (2022) TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors. Journal of Psoriasis and Psoriatic Arthritis 7:2, pages 79-92.
Crossref
Crossref
Iain B McInnes, Laura M Sawyer, Kristen Markus, Corinne LeReun, Celia Sabry-Grant & Philip S Helliwell. (2022) Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open 8:1, pages e002074.
Crossref
Crossref
Mark G. Lebwohl, Ahmed M. Soliman, Hongbo Yang, Jessie Wang, Kaitlin Hagan, Byron Padilla & Andreas Pinter. (2021) Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials. Dermatology and Therapy 12:2, pages 407-418.
Crossref
Crossref
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang, Yawen Gao, Vassilis Stakias & Luis Puig. (2021) Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy 12:1, pages 167-184.
Crossref
Crossref
Marwa Hakimi, Megan Mosca, Edward Hadeler, Julie Hong & Wilson Liao. 2022. Biologic Therapy for Psoriasis. Biologic Therapy for Psoriasis
87
99
.
M. Augustin, M. Valencia López & K. Reich. (2021) Network meta‐analyses in psoriasis: overview and critical discussion. Journal of the European Academy of Dermatology and Venereology 35:12, pages 2367-2376.
Crossref
Crossref
Paolo Gisondi, Francesco Loconsole, Paola Raimondo & Roberto Ravasio. (2021) Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment 8, pages 120-130.
Crossref
Crossref
Julia Borowczyk, Maria Shutova, Nicolo Costantino Brembilla & Wolf-Henning Boehncke. (2021) IL-25 (IL-17E) in epithelial immunology and pathophysiology. Journal of Allergy and Clinical Immunology 148:1, pages 40-52.
Crossref
Crossref
A. Blauvelt, C. Leonardi, B. Elewski, J.J. Crowley, L.C. Guenther, M. Gooderham, R.G. Langley, R. Vender, A. Pinter, C.E.M. Griffiths, Y. Tada, H. Elmaraghy, R.G. Lima, G. Gallo, L. Renda, R. Burge, S.Y. Park, B. Zhu & K. Papp. (2020) A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology 184:6, pages 1047-1058.
Crossref
Crossref
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang, Yawen Gao, Luis Puig & Matthias Augustin. (2021) Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy 11:3, pages 885-905.
Crossref
Crossref
Thomas Graier, Wolfgang Weger, Paul-Gunther Sator, Wolfgang Salmhofer, Barbara Gruber, Constanze Jonak, Claudia Kölli, Martina Schütz-Bergmayr, Igor Vujic, Gudrun Ratzinger, Nina Häring, Clemens Painsi, Knut Prillinger, Alexander Mlynek, Hans Skvara, Hannes Trattner, Adrian Tanew, Roland Lichem, Christina Ellersdorfer, Franz Legat, Alexandra Gruber-Wackernagel, Angelika Hofer, Erich Schmiedberger, Wolfram Hoetzenecker, Robert Müllegger, Werner Saxinger, Franz Quehenberger & Peter Wolf. (2021) Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD International 2, pages 62-75.
Crossref
Crossref
L. Puig. (2021) Meta-analysis and Indirect Comparisons: on Methods, Paradigms, and Biologic Treatments for Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 112:3, pages 203-215.
Crossref
Crossref
L. Puig. (2021) Metaanálisis y comparaciones indirectas. Métodos y paradigma: tratamiento biológico de la psoriasis. Actas Dermo-Sifiliográficas 112:3, pages 203-215.
Crossref
Crossref
Edward Hadeler, Megan Mosca, Julie Hong, Nicholas Brownstone, Tina Bhutani & Wilson Liao. (2021) Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports 10:1, pages 6-15.
Crossref
Crossref
Hanae Miyagawa, Hiromichi Hara, Jun Araya, Shunsuke Minagawa, Takanori Numata, Yoshinori Umezawa, Akihiko Asahina, Hidemi Nakagawa & Kazuyoshi Kuwano. (2021) Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis. PLOS ONE 16:1, pages e0245284.
Crossref
Crossref
Rhea Singh, Esther A. Balogh & Steven R. Feldman. (2020) Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports 9:4, pages 339-352.
Crossref
Crossref
Hannah A. Blair. (2020) Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs 80:12, pages 1235-1245.
Crossref
Crossref